EPISODE · Sep 23, 2013 · 9 MIN
Minimal Residual Disease (MRD) in Acute Myeloid Leukemia- Are we Ready for Individualized Risk Assessment Based on MRD?
from Journal of Clinical Oncology (JCO) Podcast
Before we can use MRD as a guide of post-remission therapy in AML, we have to standardize our methods for MRD quantification and agree on the definition of MRD-positive versus MRD-negative patients.
Embed this episode
NOW PLAYING
Minimal Residual Disease (MRD) in Acute Myeloid Leukemia- Are we Ready for Individualized Risk Assessment Based on MRD?
0:00
9:21
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 9 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on September 23, 2013.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!